Targeting renal cell carcinoma with a HIF-2 antagonist
2016 · Nature · 704 citations
https://doi.org/10.1038/nature19796
J
James Brugarolas
Texas Oncology(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
590
Papers
18.0K
Citations
64
h-index
161
i10-index
James Brugarolas is an academic researcher from Texas Oncology. The author has contributed to research in topics: Renal cell carcinoma treatment & Renal and related cancers & Cancer Genomics and Diagnostics. The author has an h-index of 64, co-authored 502 publications.
ORCID: 0000-0002-8575-499XPapers by this author
worksHIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
2019 · Clinical Cancer Research · 179 citations
https://doi.org/10.1158/1078-0432.ccr-19-1459
Modeling Renal Cell Carcinoma in Mice: <i>Bap1</i> and <i>Pbrm1</i> Inactivation Drive Tumor Grade
2017 · Cancer Discovery · 167 citations
https://doi.org/10.1158/2159-8290.cd-17-0292
De novo and salvage purine synthesis pathways across tissues and tumors
2024 · Cell · 136 citations
https://doi.org/10.1016/j.cell.2024.05.011
Metabolism of Kidney Cancer: From the Lab to Clinical Practice
2012 · European Urology · 85 citations
https://doi.org/10.1016/j.eururo.2012.09.054
Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial
2021 · International Journal of Radiation Oncology*Biology*Physics · 69 citations
https://doi.org/10.1016/j.ijrobp.2021.01.054
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat